| Antiangiogenic agent | Brand name | Company | Target biomarker molecule | Disease indication |
| Monoclonal antibodies | Ramucirumab | Cyramza® | Eli Lily | VEGFR-2 | Metastatic nonsmall cell lung carcinoma, gastric cancer, colorectal cancer | Bevacizumab | Avastin® | Genentech/Roche | VEGFR | Metastatic colorectal cancer, nonsmall cell lungs cancer, cRCC, ovarian cancer, metastatic breast cancer, glioblastoma | Cetuximab | Erbitux® | Bristol-myers squibb | EGFR | Second line treatment for colorectal cancer, squamous cell carcinoma of head and neck | Panitumumab | Vectibix® | Amgen | EGFR | Colorectal cancer | Necitumumab | Portrazza | Eli Lily | EGFR | Squamous nonsmall-cell cancer |
| TKI | Axitinib | Inlyta® | Pfizer | VEGFR1–3 and PDGFR | Metastatic hepatocellular cancer (HCC), thyroid cancer, renal cell carcinoma | Imatinib mesylate | Gleevec® | Novartis | Blocks Abelson cytoplasmic tyrokinase and PDGFR activity | Chronic myeloid leukaemia, gastrointestinal stromal tumors, myelodysplastic, myeloproliferative disease | Nintedanib | Vargatef® | Boehringer ingelheim | VEGFR, PDGFR, FGFR | Idiopathic pulmonary fibrosis, nonsmall cell lung cancer | Sunitinib malate | Sutent® | Pfizer | VEGFR1–3, PDGFR | Pancreatic cancer, RCC, gastrointestinal stroma tumor | Pazopanib | Votrient® | Novartis | VEGFR1–3, PDGFR | Metastatic renal cell cancer, advanced soft tissue sarcoma | Vandetanib | Caprelsa® | Sanofi | EGFR, VEGFR2–3, PDGFR | Pancreatic cancer, advanced metastatic renal cell cancer | Sorafenib | Nexavar® | Bayer/Onyx pharmaceuticals | VEGFR1–3, PDGFRβ, RET | Hepatocellular cancer, iodine resistant advanced thyroid carcinoma | Regorafenib | – | – | VEGFR1–3, TIE2 | Metastatic colorectal cancer, hepatocellular carcinoma, gastrointestinal stroma tumor |
| Receptor fusion protein | Aflibercept | Zaltrap® | Regeneron pharmaceuticals | VEGF A and B | Metastatic colorectal cancer |
| Aptamers | Pegaptanib sodium (NX1838) | Macugen® | Eyetech.IN/Pfizer | VEGF-165 | Macular degeneration |
|
|